European Innovation Council appeared to be the Corporate Investor, which was created in 1957.
We can highlight the next thriving fund investment areas, such as Computer, Information Technology. Among the various public portfolio startups of the fund, we may underline ultimate.ai, ultimate.ai, Desentum Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low.
The standard case for the fund is to invest in rounds with 1 partaker. Despite the European Innovation Council, startups are often financed by EASME - EU Executive Agency for SMEs, OurCrowd, Maki.vc. In the next rounds fund is usually obtained by Maki.vc, Horizon 2020, HV Holtzbrinck Ventures.
The common things for fund are deals in the range of 1 - 5 millions dollars. The important activity for fund was in 2019. The real fund results show that this Corporate Investor is 45 percentage points more often commits exit comparing to other companies. The fund is constantly included in 7-12 investment rounds annually.
|Boton Belt||Anhui, China, Wuxi|
|Brunswick||Illinois, Lake Forest, United States|
|China Chengxin Credit||Beijing, Beijing, China|
|Freedom Factory Studios||Community of Madrid, Madrid, Spain|
|Freeman Spogli||California, Los Angeles, United States|
|Gaorui Touzi||China, Guangdong, Shenzhen|
|Hengqin Gaiya Sanhao Changwai Guquan Touzi||China, Guangdong, Zhuhai|
|Hongyou Chuangye Touzi||Chengguan District, China, Lhasa|
|Intelligent Fund of Funds||-|
|Nanjing Shengshi Yangzi Fund Investment Management||China, Jiangsu, Nanjing|
|National Health Forecast (PSN)||-|
|Pharmstandard||Moscow, Moscow, Russia|
|Quick Heal Technologies||India, Maharashtra, Pune|
|Striim||California, Palo Alto, United States|
|Tsukui||Japan, Kanagawa Prefecture, Yokohama|
|Venus MedTech||China, Hangzhou, Zhejiang|
|$8M||21 Dec 2021||Israel, North District, Israel|
|$17M||20 Dec 2021||Israel, Tel Aviv District, Israel|
|$2M||19 Dec 2021||London, England, United Kingdom|
|$2M||17 Dec 2021||Lund, Skane Lan, Sweden|
|$2M||16 Dec 2021||City of Edinburgh, Scotland, United Kingdom|
|$61M||14 Dec 2021||New York, New York, United States|
|$1M||24 Nov 2021||Braga, North, Portugal|
|$2M||18 Nov 2021||Paris, Ile-de-France, France|
|$826K||01 Nov 2021||Stockholm, Stockholm County, Sweden|
– Ganymed Robotics secured a €2,5M grant through the European Innovation Council Accelerator program.
– EIC Accelerator is the most competitive public funding scheme for deeptech startups in the world, with this year over 2000 companies applying and only 65 winners.
– Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.
– Ganymed’s first application is a robotic surgical assistant for total knee arthroplasties (TKA).
– Driven by a growing and aging population, demand for orthopedic surgery is rapidly increasing and the market for TKA is expected to rise from 2.4 million procedures in 2021 to 5.7 million in 2030 in the OECD alone.
– EpiEndo Pharmaceuticals announced the closing of a €20m Series A financing round.
– The round was led by Flerie Invest and Iðunn Venture Fund, with existing investors ABC Ventures participating, along with the European Innovation Council joining the round.
– The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.
– EpiEndo’s development rationale is based on a newly acknowledged therapeutic paradigm, that loss of integrity of epithelial barriers plays a critical role in propagating chronic inflammatory diseases in lungs and contributes to vulnerability to infections associated with acute exacerbations of airway diseases.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.